

SAMPLE INFORMATION FORM

Please complete sections below in English.

PATIENT INFORMATION	
FIRST NAME	LAST NAME
DATE OF BIRTH	PATIENT GENETIC SEX
PHONE NUMBER	EMAIL
ETHNICITY	SAMPLE COLLECTION DATE
ADDRESS	
CITY PC	OST CODE COUNTRY

ORDERING HEALTHCARE PROVIDER INFORMATION			
CLINIC NAME	CLINIC ID		
REFERRING HEALTHCARE PROVIDER			
PHONE NUMBER	FAX		
EMAIL			
ADDRESS			
CITY Pr	OST CODE COUNT		

REQUESTED TEST

Evartia metabolic test Testing of 223 genes

Evartia metabolic test screens for all the following disease categories:					
3-Methylglutaconic aciduria	Fatty acid oxidation disorders	Maple syrup urine disease and DLD deficiency			
Cerebral creatine deficiency	Hyperinsulinemic hypoglycemia	Methylmalonic acidemia			
Congenital disorders of glycosylation	Hyperphenylalaninemia	Peroxisomal disorders			
Glycine encephalopathy	Lysosomal storage disorders	Urea cycle disorders			
Glycogen storage diseases					

 $\label{eq:Forthecomplete} For the complete list of the genes tested, please visit www.medicover-genetics.com$

TEST INDICATIONS				
FAMILY HISTORY (Please specify):	HIGH RISK ETHNICITY (Please specify):			
SYMPTOMS (Please specify all symptoms, including symptoms of neurological, cardiovascular, musculoskeletal, developmental nature etc.):				
BIOCHEMICAL/ENZYMATIC TEST RESULTS (Please specify test, specimen and results):	OTHER (Please specify any vision, hearing, imaging, pathology findings):			
COMMENTS:				

 $\label{eq:linear} \textit{If applicable, please attach detailed medical record and clinical information}$

FOR LABORATORY USE ONLY F-OPR-01/15-V7-EN	ORDER NUMBER	LAB ID NUMBER	KIT LOT NUMBER	
COMMENTS		DATE & TIME OF RECEIPT (DD/MM/YY HH:MM)	RECEIVED BY	
\sim	Page	1 of 4		RESTRICTED



Neas Engomis 31, Nicosia, 2409 Cyprus Phone: +357 22266888 Fax: +357 22266899

Web: www.medicover-genetics.comEmail: info.genetics@medicover.com









RESTRICTED



PATIENT CONSENT

By placing my signature below I hereby:

- 1. Confirm that I have read, or have had read to me, the attached Patient Informed Consent and that I understand it.
- 2. Declare that I have had the opportunity to receive counseling from my referring healthcare provider on the Evartia test and to discuss with the healthcare provider all aspects of the Evartia test and this form including the benefits, risks and limitations of the Evartia test as well as the reasons for performing the test and availability of alternative testing options to my satisfaction.
- 3. Authorize my referring healthcare provider to collect the necessary buccal swab sample, and to submit this form and transport the samples to Medicover Genetics laboratories for the purposes of conducting the tests requested with this form.
- 4. Authorize Medicover Genetics to use any part of or the entirety of the biological sample for the purposes of conducting the tests requested with this form.
- 5. Authorize Medicover Genetics to communicate the results of the test to my referring healthcare provider.
- 6. Confirm that all the information on this form is true to the best of my knowledge.

I wish to be informed if I am a carrier for a genetic disorder tested by the Evartia test, and give permission to Medicover Genetics to report the carrier status as an incidental finding. I confirm that I have receive counseling from my referring healthcare provider regarding a positive carrier status for one or more genetic disorders.

Your test results and any unused biological material can help Medicover Genetics improve and further develop the quality, accuracy and effectiveness of diagnosis and help us expand the scope of genetic testing. For this reason, Medicover Genetics would like to use your anonymized, de-identified (i.e. after removing all the personal information from which you can be identified) test results and unused biological material.

For the above scope, I consent to the inclusion of my test results in Medicover Genetics' database, the coding, storing and using of biological material.

PATIENT/GUARDIAN SIGNATURE DATE

HEALTHCARE PROVIDER ATTESTATION

I hereby certify and undertake that:

- 1. I am the referring healthcare professional ordering this test.
- 2. The test results will determine my patient's medical management and treatment options.
- 3. The patient has been informed about the nature and purpose of the testing.
- 4. The patient has been duly and thoroughly counseled about the test and has receivedall the advice necessary to provide their informed consent, including the benefits, risks, and limitations of the Evartia test.
- 5. I have answered all the patient's queries about the Evartia test.
- 6. This form has been completed according to the wishes and instructions of the patient.
- 7. I have obtained the patient's informed consent and have attested their signature.

HEALTHCARE PROVIDER SIGNATURE

DATE



Web: www.medicover-genetics.com Email: info.genetics@medicover.com

Page 2 of 4











F-OPR-01/15-V7-EN



PATIENT INFORMED CONSENT

Evartia TEST

Evartia screens for genetic changes (mutations) in your DNA that can cause inherited metabolic diseases. Such diseases usually manifest immediately or within weeks of birth, but depending on the mutation and the pathway involved, they could appear in childhood, early or late adulthood. Symptoms of metabolic diseases vary widely, and may include vomiting, weight loss, seizures, as well as neurological or psychiatric symptoms, heart, liver, kidney, behavioral or learning problems, and motor or respiratory abnormalities. Symptoms and metabolic episodes can also be triggered by specific foods, medication, exercise, dehydration, illness or other factors. The Evartia metabolic test can help uncover the cause of persistent, debilitating symptoms through accurate and reliable genetic testing.

The Evartia test can be useful for:

- Individuals with common symptoms of a metabolic disease
- Individuals with a spectrum of overlapping symptoms that vary in age of onset and severity
- Individuals with neurological symptoms that haven't improved with routine therapies
- Individuals with a family history of a metabolic disease

SAMPLE COLLECTION

Your healthcare provider will take one buccal swab sample following the provided sample collection instructions and send it to Medicover Genetics laboratories for analysis. Occasionally, additional sample may be needed if there is a shipping delay, breakage of the sample collection device, sample degradation, sample contamination, inadequate sample or if the sample has been submitted incorrectly.

RESULT INTERPRETATION

The results are communicated within approximately 2-4 weeks directly to your healthcare provider. The healthcare provider ordering this test is responsible to understand the specific uses and limitations of the test, communicate this information to you and answer any questions you may have. The following describes the possible results from the test:

Clinically significant variant detected: A clinically significant variant (change) indicates that a pathogenic or likely pathogenic genetic variant has been identified in a gene associated with a metabolic disease. It is possible that the test identifies more than one clinically significant variant. The results should be interpreted in the context of the patient's clinical findings, symptoms, biochemical profile or family history.

No clinically significant variant detected: No clinically significant variant detected indicates that no disease-causing genetic variant has been idenfitied for the test performed. A 'no clinically significant variant detected' result does not rule out any pathogenic variants in areas not assessed by the test, or in regions that were covered at a level too low to assess. A result of 'no clinically significant variant' does not guarantee that the individual will be healthy or free from genetic disorders or medical conditions.

Variant of Uncertain Significance (VUS): A VUS indicates that a genetic change has been detected, but it is currently unknown whether that change is associated with a genetic disorder. More scientific research and data are needed to clarify VUS and their role in disease. VUS will only be reported in

cases of potential pathogenicity. The carrier status in recessive conditions will not be reported. In case of a VUS result, further analysis may be recommended by your healthcare provider. Detailed medical records or information from other family members may also be needed by your healthcare provider, in combination with clinical counseling to help clarify results.

Result interpretation is based on currently available information in the medical literature, research and scientific databases. Because the literature, medical and scientific knowledge are constantly changing, new information that becomes available in the future may replace or add to the information currently known. It is recommended that you keep in contact with your referring healthcare professional to learn of any changes in your interpretation of your results or new developments.

DISCLOSURE

Medicover Genetics is a fully accredited state-of-the-art genetic testing laboratory. All necessary measures are taken to perform the testing reliably and under strict standards. Evartia is highly accurate, however, there is a small possibility for false positive, false negative or inconclusive results due to technical and biological reasons. Although rare, these reasons include but are not limited to: mislabeled samples, inaccurate reporting of clinical/medical information, rare technical errors, or other rare events such as the presence of change(s) in such a small percentage of cells that the change(s) may not be detectable by the test (mosaicism). The analysis is specific only for the tests ordered. This test will not detect all genetic changes in the evaluated genes. Some undetected genetic changes could be disease-related and are not tested by Evartia. A healthy carrier status is not reported by the Evartia test. If you wish to be informed whether you are a carrier for any of the disorders tested by Evartia, please select the appropriate option on page 2 of the SIF, and the carrier status will be reported as an incidental finding. Genetic testing is an important part of the diagnostic process. However, genetic tests may not always give a definitive answer. In some cases, testing may not identify a genetic change even though one exists. This may be due to limitations in current medical knowledge or testing technology. Accurate interpretation of test results is dependent upon the patient's clinical diagnosis or family history, as well as the fact that any reported family relationships are true biological relationships. This test does not have the ability to detect all the long-term medical risks. Other diagnostic tests may still be necessary.

BENEFITS

Your genetic test results may help you and your doctor make informed choices about your family planning, healthcare and management. The results of genetic testing may have implication on other blood relatives. It is recommended that you receive genetic counseling before and after having this genetic test.

QUALITY IMPROVEMENT

Please choose the relevant option on the consent form to grant us permission to anonymously use your remaining sample to improve the quality, accuracy and effectiveness of Evartia.

Pleasemakesureyoureadandunderstandtheinformationonthisdocumentbeforesigning and complete all relevant information accurately as incorrect information can lead to inaccurate test results. Please discuss any questions you may have with your healthcare provider. For additional information please visit our website at **www.medicover-genetics.com**.



Web: www.medicover-genetics.com Email: info.genetics@medicover.com

Page 3 of 4











F-OPR-01/15-V7-EN



PATIENT PRIVACY SUMMARY

This privacy notice provides a summary of how Medicover Genetics Limited collects and processes your personal data with this form. It is important that you read this privacy notice together with our full privacy policy which contains more detailed information about our data processing. A copy is available online at www.medicover-genetics.com

1. Important information and who we are

Medicover Genetics is responsible for processing the personal data collected on this form.

We have appointed a data protection officer (DPO). If you have any questions about this privacy notice or our data protection practices, please contact the DPO.

CONTACT DETAILS

Full name of legal entity: Medicover Genetics Limited (HE 418406) Email address: dpo.cy@medicover.com Postal address: 31 Neas Engomis Street, 2409 Engomi, Nicosia, Cyprus Telephone number: + (357) 22266888

2. The data we collect about you

We collect, use, store and transfer personal data about you as follows:

- Identity Data.
- Contact Data.
- Sensitive Data (ethnicity, patient genetic sex, medical/clinical data).

3. How we use your personal data

We will only use your personal data for the purpose for which we collected it. This includes the following:

- To register you as a new customer.
- To conduct your selected test and to process and deliver your results.
- To manage your relationship with us and to provide customer support, where applicable.
- To contact you or your referring healthcare provider on your results.
- To invoice the referring healthcare provider.

4. How we share your personal data

We share your personal data with your referring healthcare provider, so we can communicate the results of your test to them. Medicover Genetics stores personal information on its database which is hosted by cloud service providers.

5. International transfers

We do not transfer, store or process your personal data outside the European Economic Area (EEA) unless you or your referring healthcare provider are located outside the EEA.

6. Your legal rights

Under certain circumstances, you have rights under data protection laws in relation to your personal data including the right to receive a copy of the personal data we hold about you, the right to erasure ('right to be forgotten'), the right to restriction of processing and the right to make a complaint at any time to the Office of the Commissioner for Personal Data Protection.



Web: www.medicover-genetics.com Email: info.genetics@medicover.com

Page 4 of 4











F-OPR-01/15-V7-EN